en · de · es
sr9009-notes.peptides7501.com › Info › Analytical Detection And Regulatory Status — Evidence Review

Analytical Detection And Regulatory Status — Evidence Review

By Editorial Desk · published 2026-02-13 · last reviewed 2026-03-19 · Info

LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useInvestigational status in most countries
Sports statusProhibited by WADAClassified as non-approved or metabolic modulator
Common analytical methodLC-MS/MSUsed for trace detection in biological samples
Typical test matricesUrine and bloodSample choice depends on testing program
Human trial dataNone publishedEffects and safety are not established

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Related pages on this site

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Supporting material

== Menu == Jimmy John's has three bread options: French, thick-sliced wheat, and the six-inch "Lil' John" (smaller version of French bread), as well as a lettuce-wrap option known as the Unwich, and a tortilla-wrap option. Jimmy John's has 17 different numbered sandwiches plus a B.L.T., called the J.J.B.L.T, and the Gargantuan, which includes all the meats except bacon and tuna. The 17 sandwiches may have ham, roast beef, tuna, turkey, salami, capicola, bacon, provolone cheese or parmesan cheese, or combine two or more meats and cheese. Jimmy John's has four flavors of chips, including regular, BBQ, jalapeño, and salt and vinegar. The menu also includes kosher dill pickles as well as brownies and "triple chunk" chocolate and oatmeal raisin cookies. In 2021, Jimmy John's began introducing limited-time offers to its menu. The company introduces two to three limited-time offers a year, starting with the "Smokin’ Kickin' Chicken" sandwich in February 2021. Their summer wraps, which started as a limited time offer, became a permanent installation in 2023. In March 2025, Jimmy John's introduced a new line of toasted sandwiches.

== Comorbidity == Fibromyalgia as a stand-alone diagnosis is uncommon, as most fibromyalgia patients often have other chronic overlapping pain problems, mental disorders or other medical conditions. Comorbidities may be associated with more intense pain and other symptoms. Fibromyalgia is associated with mental health issues, including anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, alexithymia, and depressive disorders. Approximately one-third of patients presenting with an FM diagnosis also meet the criteria for PTSD, and are five times more likely to have major depressive disorder than the general population. The pain and limited energy of fibromyalgia often leads to less activity, leading to social isolation and increased stress levels—both of which tend to cause anxiety and depression. Separation of depression symptoms from those of fibromyalgia is difficult. Chronic pain conditions are often comorbid with fibromyalgia, including neuropathic pain, chronic tension headaches, myofascial pain syndrome, and temporomandibular joint dysfunction. Neurological disorders that have been linked to pain or fibromyalgia include multiple sclerosis, post-polio syndrome, and Parkinson's disease. Fibromyalgia may share pathogenetic overlap with other syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome (IBS). Fibromyalgia has been reported to occur as a comorbidity in 20–30% of individuals with rheumatic diseases, including rheumatoid arthritis (RA).

A cocurrent heat exchanger is an example of a cocurrent flow exchange mechanism. Two tubes have a liquid flowing in the same direction. One starts off hot at 60 °C (140 °F), the second cold at 20 °C (68 °F). A thermoconductive membrane or an open section allows heat transfer between the two flows. The hot fluid heats the cold one, and the cold fluid cools down the warm one. The result is thermal equilibrium: Both fluids end up at around the same temperature: 40 °C (104 °F), almost exactly between the two original temperatures (20 °C (68 °F) and 60 °C (140 °F)). At the input end, there is a large temperature difference of 40 °C (104 °F) and much heat transfer; at the output end, there is a very small temperature difference (both are at the same temperature of 40 °C (104 °F) or close to it), and very little heat transfer if any at all. If the equilibrium—where both tubes are at the same temperature—is reached before the exit of the liquid from the tubes, no further heat transfer will be achieved along the remaining length of the tubes. A similar example is the cocurrent concentration exchange. The system consists of two tubes, one with brine (concentrated saltwater), the other with freshwater (which has a low concentration of salt in it), and a semi permeable membrane which allows only water to pass between the two, in an osmotic process. Many of the water molecules pass from the freshwater flow in order to dilute the brine, while the concentration of salt in the freshwater constantly grows (since the salt is not leaving this flow, while water is).

Sources: en.wikipedia.org

Notes from published material

conjugative - mediate DNA transfer through conjugation and therefore spread rapidly among the bacterial cells of a population; e.g., F plasmid, many R and some col plasmids. nonconjugative - do not mediate DNA through conjugation, e.g., many R and col plasmids.

Trump consistently supported Israel, though presented himself as the "candidate of peace". Trump also supported giving weapons to Israel, likely with "no strings attached", saying that it must "finish the problem". Trump was seen by some as more pro-Israel and less sympathetic to Palestine than Biden or Harris. Trump took a hardline stance against pro-Palestinian protests, telling donors he would "crush" them and deport non-citizen protestors to "set the movement back 25 or 30 years". At times, Trump was critical of Israel's conduct, saying Israel should "get it over with ... get back to peace and stop killing people". However, he pledged to end the war in Gaza through negotiation and bring peace to the Middle East. Trump called Biden's airstrikes on Yemen "crazy" and suggested negotiating with the Houthis.

===== Topical ===== Some popular plant juices sold as hair serum may, instead of growing human hair, actually inhibit the growth, including 6-gingerol found in ginger. Among the indigenous peoples of California, plants in the genus Marah were used as a topical treatment for hair loss, with the seeds roasted, mashed, and applied to the scalp as a salve. The cucurbitacins found in Marah are structurally similar to finasteride.

Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in people who inject substances and sex-workers. HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk of acquiring and transmitting HIV.

Sources: en.wikipedia.org

Background from the literature

fingerprick type of glucose meter - need to prick self finger 8-12 times a day. continuous glucose monitor - the CGM monitors the glucose levels every 5 minutes approximately. Laboratory tests are often used to diagnose illnesses and such methods include

== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Silva, Robert J. (2011). "Chapter 13. Fermium, Mendelevium, Nobelium, and Lawrencium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer. doi:10.1007/978-94-007-0211-0_13. ISBN 978-94-007-0210-3. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.

==== Side effects and toxicity ==== The most common side effect is diarrhea and dyspepsia, occurring in up to 30% of patients. The most important and serious side effect is lactic acidosis, therefore metformin is contraindicated in advanced chronic kidney disease. Kidney function should be assessed before starting metformin. Phenformin and buformin are more prone to cause acidosis than metformin; therefore they have been practically replaced by it. However, when metformin is combined with other drugs (combination therapy), hypoglycemia and other side effects are possible.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Why is SR9009 prohibited in sport?

Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.

How is SR9009 detected in samples?

Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network